Drug
Compound 451238
Compound 451238: highest development phase Phase 1/2, developed by Merck KGaA. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Merck KGaA
Trials
| Drug | Phase | Indication |
|---|---|---|
| Compound 451238 NCT03602833 | Phase 1/2 | Soft-tissue Sarcoma |
Latest
No recent events.
Follow Compound 451238 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.